comparemela.com

Latest Breaking News On - Clinical lymphoma - Page 3 : comparemela.com

Real-World Data Show Suboptimal Efficacy With AZA in Treatment-Naïve High-Risk MDS

Pulling data from a US electronic health record–based database, researchers found low rates of complete remission and poor overall survival among 382 patients who had myelodysplastic syndromes (MDS) receiving first-line azacytidine (AZA).

Steroid, rituximab use can lead to secondary immunodeficiencies

Steroid, rituximab use can lead to secondary immunodeficiencies
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

Ixazomib Shows Efficacy, Tolerability in Real-World R/R Multiple Myeloma Treatment

A study of patients with relapsed or refractory (R/R) multiple myeloma who received ixazomib-based therapy in real-world settings found the treatment effective and tolerable in clinical practice.

Telo Genomics Presents Positive Results in Assessing MRD in Multiple Myeloma Patients at the International Myeloma Society Annual Meeting

Telo Genomics Presents Positive Results in Assessing MRD in Multiple Myeloma Patients at the International Myeloma Society Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Telo Genomics Corp : Telo Genomics Presents Positive Results in Assessing MRD in Multiple Myeloma Patients at the International Myeloma Society Annual Meeting

Telo Genomics Corp : Telo Genomics Presents Positive Results in Assessing MRD in Multiple Myeloma Patients at the International Myeloma Society Annual Meeting
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.